DLX 0201

Drug Profile

DLX 0201

Alternative Names: DLX0201

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator DELEX Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Nausea and vomiting

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nausea and vomiting in Canada
  • 04 May 2005 DELEX Therapeutics has been acquired by YM BioSciences
  • 27 Aug 2003 Preclinical trials in Emesis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top